Additionally, the potential of DGKη to regulate MAPK signaling, which is a downstream target of epidermal growth factor receptor (EGFR), led a group to study the oncogenic effects of DGKη in lung cancer, which is often characterized by mutations in EGFR and KRAS. The gene discussed is KRAS; the disease is lung cancer.